Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn’s disease

Table 3 Distribution of IL-10G14 allele among the different clinical subgroups of CD stratified by NOD2/CARD15 status

Phenotypic characteristics	Phenotypefrequencyof IL-10.G14 (+)(n=47) (%)	P	CARD15/NOD2 (+) IL-10.G14,(n = 22) (%)	P	CARD15/NOD2 (-)IL-10.G14,(n = 25) (%)	P
Sex
Men	23 (48.9)	0.74	13 (59.1)	0.08	10 (40)	0.32
Women	24 (51.1)		9 (40.9)		15 (60)
Age at diagnosis (yr)
A1, < 40	39 (83.0)	0.5	21 (95.5)	0.27	18 (72)	0.68
A2, ≥40	8 (17.0)		1 (4.5)		7 (28)
Family history	9 (19.1)	0.54	4 (18.2)	0.52	5 (20)	0.88
Smokers	24 (51.1)	0.51	16 (72.7)	0.021	8 (32)	0.41
Appendectomy	9 (19.1)	0.32	6 (27.3)	0.0022	3 (12)	0.59
Tonsillectomy	5 (10.6)	0.63	3 (13.6)	0.48	2 (8)	0.36
Disease behavior
Nonstricturing, nonpenetrating (B1)	19 (40.4)	0.61	6 (27.3)	0.19	13 (52)	0.62
Stricturing (B2)	9 (19.1)		6 (27.3)		3 (12)
Penetrating (B3)	19 (40.4)		10 (45.5)		9 (36)
Location of disease
Terminal ileum (L1)	23 (48.9)	0.26	15 (68.2)	0.54	8 (32)	0.24
Colon (L2)	4 (8.5)		1 (4.5)		3 (12)
Ileocolon (L3)	17 (36.2)		5 (22.7)		12 (48)
Upper gastrointestinal (L4)	3 (6.4)		1 (4.5)		2 (8)
Perianal	14 (29.8)	0.86	4 (18.2)	0.47	10 (40)	0.28
Extraintestinal clinical manifestations
Cutaneous	8 (17.0)	0.62	3 (13.6)	0.3	5 (20)	0.56
Articular	13 (27.7)	0.32	6 (27.3)	0.53	7 (28)	0.36
Treatment
Surgical intervention	20 (42.6)	0.98	10 (45.5)	0.8	10 (40)	0.82
Infliximab	7 (14.9)	0.79	5 (22.7)	0.31	2 (8)	0.21
Immunosuppressants	18 (38.3)	0.61	10 (45.5)	0.81	8 (32)	0.23

¹IL-10G14 in NOD2/CARD2 mutation positive patients: smokers vs non-smokers (P = 0.02, RR = 2.47, 95%CI = 1.28-4.8).

²IL-10 G14 in NOD2/CARD2 mutation positive patients: appendectomy vs non-appendectomy (P = 0.002, RR = 3.29, 95%CI = 1.45-7)